



Bigtec Private Limited Company Profile

Bigtec Labs, which has a cutting-edge 20,000 sq.ft research and development facility recognized by DSIR (the Government of India's Department for Scientific & Industrial Research), was established in Bangalore, India in 2000.

Back in 2005, the team at Bigtec had a vision to develop a portable diagnostic platform for infectious diseases that could be deployed at Primary Healthcare Centres. Our design was carefully crafted to address all the related constraints, and we executed it flawlessly. Today, Bigtec is playing a crucial role in India's fight against Covid-19 and TB by providing diagnostic solutions that can deliver results in as little as 60 minutes. One of our goals is to assist India in bolstering its Ayushman Bharat program by providing infrastructure to strengthen Primary Healthcare.

Our focus is primarily on the healthcare and homeland security sectors, and we strive to meet the current needs of these industries. The company's primary objective in healthcare is to pioneer the development of innovative point-of-care solutions and products in the field of clinical diagnostics and biosensors for resource-limited settings across the globe. This, in turn, enables patients to receive the appropriate treatment at an early stage, leading to a faster return to good health.

Bigtec Labs utilizes a wide range of capabilities, including design, fabrication, and testing of Micro Electromechanical Systems (MEMS) and handheld electronics, as well as expertise in genomics and proteomics, microbiology, and chemistry. By leveraging this diverse set of skills, Bigtec Labs has successfully developed the world's first-ever near-care Polymerase Chain Reaction (PCR) platform for clinical diagnosis. These microfluidic devices that can detect pathogens on-chip (Truenat), addressing a crucial need in the healthcare industry created a global impact. This lab-on-chip technology is aimed at creating systems that can perform sample preparation, mixing, complex bio-chemical reactions, sample screening, and detection all on a single chip platform.

This innovation frees the technology from the laboratory's confines, making it possible to perform nucleic acid amplification tests (NAAT) wherever they are most needed, closer to a patient's initial interaction with the healthcare system. By decentralizing and democratizing NAAT testing, we enable the highly sensitive and specific diagnosis of infectious diseases. The Truelab platform was developed with the unique constraints of resource-limited settings in mind and requires minimal training and only basic infrastructure at the point of deployment.

In order to maximize its capabilities, Bigtec has established several professional partnerships aimed at creating synergies with various domestic and international universities and institutions to build a robust academic and advisory foundation. Our multidisciplinary team has developed this technology and platform from the ground up. We intend to continue to leverage our skills and expertise to create other such ground-breaking technologies that address clinical needs while keeping resource-limited settings in mind. Our ultimate goal is to facilitate superior healthcare by providing precise, faster, and cost-effective diagnostic solutions at the point of care through the use of portable devices.

Our Products

- **BEAGLEZ – Handheld Explosive Detector**
- **Truelab™ Real Time micro PCR Platform**
- **Truepep™ AUTO-Universal Cartridge based Sample Prep Device**
- **TrueLab™ Portable PCR Platform**
- **More than 30 Truenat products which are disease specific**

Few of Our Milestones:

- **Molbio Diagnostics, the parent company of Bigtec Labs, secured \$85 million in funding at a unicorn valuation, becoming the 108th unicorn, a rare distinction in the medical device industry. Molbio Diagnostics is the only medical device company to make it to India's top 500 firms, ranking at the 275th position, which is a significant achievement.**
- **Dr. Chandrasekhar Nair, Director of Bigtec Private Limited, was awarded 'The Infosys Prize 2021' in the Engineering and Computer Science category. This award recognized his contribution to the development and large-scale commercialization of Truenat.**
- **Molbio Diagnostics received a maximum investment of INR 240 Crore from Motilal Oswal Private Equity funds.**
- **Bigtec Labs received the commendation certificate for GST Tax Payer in 2022 from the Honourable Finance Minister Smt. Nirmala Sitharaman at Vigyan Bhavan, New Delhi.**
- **Molbio Diagnostics was honoured with the BW Healthcare World Excellence Award 2022.**

- **Truenat MTB, developed by Bigtec Labs, has received endorsement from the World Health Organization (WHO), which is a significant validation of its quality and effectiveness.**
- **The then honourable Chief Minister of Andhra Pradesh launched our Truenat product in AP as a replacement for microscopy, recognizing the value it provides in accurate and timely diagnosis.**
- **We have showcased our products in various expos and exhibitions worldwide to highlight their capabilities and benefits.**

Facts

- **The Truenat Device is capable of detecting more than 30 diseases, and has gained significant recognition for its effectiveness in testing for Tuberculosis and Covid-19.**
- **We have installed over 8,500 devices in 30+ countries around the world.**
- **Manufacturing capacity of 100,000 tests per day**
- **Over 12 million covid tests performed across India**
- **14 countries are now deploying Truenat under STOP TB /USAID New Tools Project**